David Rodman
2023
In 2023, David Rodman earned a total compensation of $2.3M as Chief Medical Officer at Mineralys Therapeutics, a 112% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $213,750 |
|---|---|
| Option Awards | $1,620,457 |
| Salary | $500,000 |
| Other | $13,200 |
| Total | $2,347,407 |
Rodman received $1.6M in option awards, accounting for 69% of the total pay in 2023.
Rodman also received $213.8K in non-equity incentive plan, $500K in salary and $13.2K in other compensation.
Rankings
In 2023, David Rodman's compensation ranked 431st out of 3,006 executives tracked by ExecPay. In other words, Rodman earned more than 85.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 431 out of 3,006 | 86th |
Division Manufacturing | 245 out of 1,650 | 85th |
Major group Chemicals And Allied Products | 172 out of 918 | 81st |
Industry group Drugs | 169 out of 881 | 81st |
Industry Pharmaceutical Preparations | 107 out of 637 | 83rd |
Source: SEC filing on April 9, 2024.
Rodman's colleagues
We found two more compensation records of executives who worked with David Rodman at Mineralys Therapeutics in 2023.